Is Mobocertinib a safety agent?

Mobocertinib (Mobocertinib) is a brand name used in the domestic market. It belongs to the third generation of EGFR inhibitors The agent represents an important advance in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC), aiming to provide more effective treatment options and help improve patients' survival and quality of life. The development of this drug represents continued innovation and improvement in cancer treatment in the medical field. Mobosetinibhas been approved by the State Food and Drug Administration for marketing in China, but it has not yet been included in medical insurance. The price of 40mg*112 capsules per box is around 40,000 yuan, which is very high.